22 completed, 7 terminated, 1 unknown, 1 withdrawn. 17 Phase 2, 15 Phase 1, 1 Early Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 17 | Completed 12, Terminated 4, Unknown 1 |
| Phase 1 | 15 | Completed 10, Terminated 4, Withdrawn 1 |
| Early Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Completed 1 |
Follow Buparlisib: new trials by email Literature Review of Buparlisib trials Research Report on Buparlisib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma Buparlisib, Ibrutinib - Lymphoma, Mantle Cell Lymphoma | Phase 1 | Completed | Memorial Sloan Kettering Cancer Center | 37 | 2016-05-09 | 2022-10-10 |
| Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia Buparlisib, Ibrutinib, Ofatumumab - Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 1 | Terminated | Emory University | 1 | 2016-01-01 | 2019-09-03 |
| Buparlisib, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Advanced Solid Tumors Buparlisib, Cisplatin, Gemcitabine Hydrochloride - Adult Solid Neoplasm, Recurrent Non-Small Cell Lung Carcinoma | Phase 1 | Withdrawn | Roswell Park Cancer Institute | 2015-09-01 | 2023-04-27 | |
| Buparlisib in Melanoma Patients Suffering From Brain Metastases (BUMPER) Buparlisib - Malignant Melanoma, Metastases | Phase 2 | Unknown | University Hospital Tuebingen | 22 | 2015-07-01 | 2017-05-03 |
| Buparlisib in Patients With Relapsed and Refractory Chronic Lymphocytic Leukemia Buparlisib - Chronic Lymphocytic Leukemia | Phase 2 | Completed | Canadian Cancer Trials Group | 14 | 2015-04-27 | 2023-08-22 |
| Pilot Study of Sonidegib and Buparlisib in Treating Patients With Advanced or Metastatic Basal Cell Carcinoma Buparlisib, Sonidegib - Carcinoma, Basal Cell, Recurrent Skin Cancer | Phase 2 | Terminated | Anne Chang | 10 | 2015-02-01 | 2019-01-29 |
| Trial of BKM120/Tamoxifen-combination in Patients With HR-pos, HER2-neg Breast Cancer BKM120, Tamoxifen - Breast Cancer | Phase 2 | Completed | University Hospital, Essen | 48 | 2014-12-01 | 2018-04-20 |
| Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck BKM120, Cisplatin, Intensity-modulated radiotherapy (IMRT) - Carcinoma, Squamous Cell of Head and Neck, HPV Positive Oropharyngeal Squamous Cell Carcinoma | Phase 1 | Completed | Dana-Farber Cancer Institute | 23 | 2014-09-29 | 2024-11-05 |
| Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer. LEE011, Buparlisib, Letrozole - Advanced or Metastatic Breast Cancer | Phase 1 | Completed | Novartis Pharmaceuticals | 13 | 2014-06-27 | 2020-12-19 |
| STAR Cape+BKM120 MBC With Brain Met BKM120, capecitabine, Trastuzumab - Brain Metastases, Breast Cancer | Phase 2 | Completed | US Oncology Research | 10 | 2014-05-29 | 2022-02-07 |
| Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women alpelisib, buparlisib, Placebo - Breast Cancer | Phase 2 | Completed | Novartis Pharmaceuticals | 340 | 2014-03-11 | 2018-09-14 |
| Pharmacokinetic Study of Buparlisib in Subjects With Renal Impairment. Buparlisib - Renal Impairment | Phase 1 | Completed | Novartis Pharmaceuticals | 19 | 2014-03-01 | 2020-12-09 |
| Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme buparlisib, carboplatin, lomustine - Recurrent Glioblastoma Multiforme | Phase 1 | Completed | Novartis Pharmaceuticals | 35 | 2014-02-28 | 2020-12-09 |
| Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Glioblastoma INC280, Buparlisib - c-MET Inhibitor; PI3K Inhibitor, PTEN Mutations, Homozygous Del. of PTEN or PTEN Neg. by IHC, c-Met Ampli. by FISH, INC280, BKM120, Buparlisib; Recurrent GBM | Phase 1 / Phase 2 | Terminated | Novartis Pharmaceuticals | 43 | 2014-01-09 | 2018-05-30 |
| Study of Efficacy and Safety of Buparlisib (BKM120) Plus Paclitaxel Versus Placebo Plus Paclitaxel in Recurrent or Metastatic Head and Neck Cancer Previously Pre-treated With a Platinum Therapy Buparlisib, Buparlisib matching Placebo, Paclitaxel - Head and Neck Squamous Cell Carcinoma | Phase 2 | Terminated | Novartis Pharmaceuticals | 157 | 2013-10-01 | 2018-07-24 |
| Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients Buparlisib, Buparlisib matching placebo, Docetaxel - Squamous Non-small Cell Lung Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 27 | 2013-10-01 | 2018-08-14 |
| Safety and Efficacy of Buparlisib (BKM120) in Patients With Untreated Squamous Non-small Cell Lung Cancer Buparlisib, Buparlisib placebo, Carboplatin - Non-Small Cell Lunch Cancer | Phase 1 | Terminated | Novartis Pharmaceuticals | 6 | 2013-09-09 | 2018-10-11 |
| PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer PI3K inhibitor BKM120, pemetrexed disodium, carboplatin - Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer | Phase 1 | Completed | City of Hope Medical Center | 9 | 2013-07-01 | 2016-09-20 |
| Neoadjuvant BKM120 in High-risk Prostate Cancer BKM120 - High Risk Prostate Cancer | Phase 2 | Terminated | Won Kim | 11 | 2013-04-23 | 2021-01-13 |
| Palliative Thoracic Radiotherapy Plus BKM120 BKM120 - Carcinoma, Non-Small-Cell Lung | Phase 1 | Completed | University of Oxford | 21 | 2013-04-01 | 2019-08-01 |
Showing 20 of 31. Sign in to see all of them.
Neoplasm Metastasis (7) · Breast Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (4) · Glioblastoma (3) · Lymphoma, Follicular (3) · Lymphoma, Large B-Cell, Diffuse (3) · Lymphoma, Mantle-Cell (3) · Brain Neoplasms (2) · Hereditary Sensory and Autonomic Neuropathies (2) · Leukemia, Lymphocytic, Chronic, B-Cell (2) · Lung Neoplasms (2) · Recurrence (2) · Squamous Cell Carcinoma of Head and Neck (2) · Basal Cell Nevus Syndrome (1) · Carcinoma, Basal Cell (1)
Novartis Pharmaceuticals (12) · Dana-Farber Cancer Institute (2) · Emory University (2) · Memorial Sloan Kettering Cancer Center (2) · Anne Chang (1) · Canadian Cancer Trials Group (1) · Centre Leon Berard (1) · City of Hope Medical Center (1) · Mayo Clinic (1) · Roswell Park Cancer Institute (1) · SCRI Development Innovations, LLC (1) · UNC Lineberger Comprehensive Cancer Center (1) · US Oncology Research (1) · University Hospital Tuebingen (1) · University Hospital, Essen (1)
United States (25) · Germany (12) · Spain (11) · Canada (8) · France (8) · Italy (8) · Belgium (7) · Australia (5) · Japan (5) · Brazil (4) · Netherlands (4) · South Korea (4) · United Kingdom (4) · Czechia (3) · Hong Kong (3)
Alex Adjei (1) · Anja Welt, MD (1) · Anne Lynn Chang, MD (1) · Autumn McRee, MD (1) · Connie Batlevi, MD, PhD (1) · Dean Bajorin, MD (1) · Geoff Higgins, MRCP, FRCR, D.Phil (1) · Glenn J. Hanna, MD (1) · Jonathon Cohen, MD, MS (1) · Joyce A. O'Shaughnessy, MD (1) · Karen Reckamp (1) · Kent Shih, MD (1) · Morris D. Groves, MD, JD (1)
PMID 26098748, PMID 28131786, PMID 28971900, PMID 29175429, PMID 30723140, PMID 31776899, PMID 32154751, PMID 32665311, PMID 33004905, PMID 33138866, PMID 34615723, PMID 39808408
2014 (1), P30CA015083 (1)